Search people, articles, bills, and more
Voters should care about this bill because it addresses concerns about rising prescription drug costs and the complex role of middlemen, Pharmacy Benefit Managers (PBMs), in the drug supply chain. If this bill becomes law, it could make drug prices more transparent for Medicare patients by ensuring rebates are applied at the point of sale, potentially lowering immediate out-of-pocket expenses.
It could also stabilize payments for local pharmacies, which often struggle with PBM reimbursement practices, potentially helping them stay in business and maintain access to care in communities. Without this bill, PBMs would likely continue current practices, meaning rebates might not directly reduce patient costs at the pharmacy, and pharmacy reimbursements would remain subject to less regulated PBM practices.
No reactions yet. Be the first to weigh in.
Voters should care about this bill because it addresses concerns about rising prescription drug costs and the complex role of middlemen, Pharmacy Benefit Managers (PBMs), in the drug supply chain. If this bill becomes law, it could make drug prices more transparent for Medicare patients by ensuring rebates are applied at the point of sale, potentially lowering immediate out-of-pocket expenses.
It could also stabilize payments for local pharmacies, which often struggle with PBM reimbursement practices, potentially helping them stay in business and maintain access to care in communities. Without this bill, PBMs would likely continue current practices, meaning rebates might not directly reduce patient costs at the pharmacy, and pharmacy reimbursements would remain subject to less regulated PBM practices.
An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)